Cortexyme Stock Forecast, Price & News

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRTX stock has increased by 33.0% and is now trading at $49.22.
View which stocks have been most impacted by COVID-19.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cortexyme or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Cortexyme a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cortexyme wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Cortexyme is scheduled to release its next quarterly earnings announcement on Tuesday, March 16th 2021.
View our earnings forecast for Cortexyme.

Cortexyme, Inc. (NASDAQ:CRTX) posted its quarterly earnings results on Tuesday, November, 17th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.11.
View Cortexyme's earnings history.

4 analysts have issued 1-year price targets for Cortexyme's stock. Their forecasts range from $59.00 to $76.00. On average, they anticipate Cortexyme's stock price to reach $68.33 in the next year. This suggests a possible upside of 38.8% from the stock's current price.
View analysts' price targets for Cortexyme.

Cortexyme saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,990,000 shares, an increase of 26.8% from the October 31st total of 1,570,000 shares. Based on an average daily volume of 110,100 shares, the days-to-cover ratio is currently 18.1 days. Currently, 16.5% of the shares of the company are sold short.
View Cortexyme's Short Interest.

Some companies that are related to Cortexyme include Cerner (CERN), Omnicell (OMCL), HMS (HMSY), Allscripts Healthcare Solutions (MDRX), Vocera Communications (VCRA), HealthStream (HSTM) and Computer Programs and Systems (CPSI).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Tilly's (TLYS).

(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Cortexyme's stock is owned by a number of institutional and retail investors. Top institutional investors include EPIQ Capital Group LLC (11.58%), BlackRock Inc. (3.26%), State Street Corp (0.97%), Pacific Heights Asset Management LLC (0.76%), Charles Schwab Investment Management Inc. (0.31%) and SG Americas Securities LLC (0.19%). Company insiders that own Cortexyme stock include David Lamond, Epiq Capital Group, Llc and Pfizer Inc.
View institutional ownership trends for Cortexyme.

CRTX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Natixis, Victory Capital Management Inc., Wells Fargo & Company MN, Alps Advisors Inc., Alps Advisors Inc., Morgan Stanley, and Letko Brosseau & Associates Inc..
View insider buying and selling activity for Cortexyme.

CRTX stock was purchased by a variety of institutional investors in the last quarter, including EPIQ Capital Group LLC, Pacific Heights Asset Management LLC, BlackRock Inc., Charles Schwab Investment Management Inc., SG Americas Securities LLC, Schonfeld Strategic Advisors LLC, Jane Street Group LLC, and Boothbay Fund Management LLC. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Pfizer Inc.
View insider buying and selling activity for Cortexyme.

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRTX stock can currently be purchased for approximately $49.22.

Cortexyme has a market capitalization of $1.45 billion. The biopharmaceutical company earns $-36,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cortexyme employs 23 workers across the globe.

The official website for Cortexyme is www.cortexyme.com.

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (650) 910-5717 or via email at [email protected]